ATE476652T1 - Quantitative assays für ras p21 in körperflüssigkeiten - Google Patents

Quantitative assays für ras p21 in körperflüssigkeiten

Info

Publication number
ATE476652T1
ATE476652T1 AT06785512T AT06785512T ATE476652T1 AT E476652 T1 ATE476652 T1 AT E476652T1 AT 06785512 T AT06785512 T AT 06785512T AT 06785512 T AT06785512 T AT 06785512T AT E476652 T1 ATE476652 T1 AT E476652T1
Authority
AT
Austria
Prior art keywords
preneoplastic
ras
total ras
patient
monitor
Prior art date
Application number
AT06785512T
Other languages
English (en)
Inventor
Walter Carney
Peter Hamer
Karen Pierce
Sheryl Brown-Shimer
Original Assignee
Siemens Healthcare Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics filed Critical Siemens Healthcare Diagnostics
Application granted granted Critical
Publication of ATE476652T1 publication Critical patent/ATE476652T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Devices For Use In Laboratory Experiments (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06785512T 2005-06-23 2006-06-23 Quantitative assays für ras p21 in körperflüssigkeiten ATE476652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69408205P 2005-06-23 2005-06-23
PCT/US2006/024647 WO2007002505A1 (en) 2005-06-23 2006-06-23 Quantitative assays for ras p21 in body fluids

Publications (1)

Publication Number Publication Date
ATE476652T1 true ATE476652T1 (de) 2010-08-15

Family

ID=37595465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06785512T ATE476652T1 (de) 2005-06-23 2006-06-23 Quantitative assays für ras p21 in körperflüssigkeiten

Country Status (8)

Country Link
US (2) US20100167324A1 (de)
EP (1) EP1893997B1 (de)
JP (1) JP4693902B2 (de)
AT (1) ATE476652T1 (de)
CA (1) CA2612693C (de)
DE (1) DE602006015957D1 (de)
ES (1) ES2349660T3 (de)
WO (1) WO2007002505A1 (de)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081230A (en) * 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US5443956A (en) * 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US6200764B1 (en) * 1985-01-29 2001-03-13 Bayer Corporation Detection, quantitation and classification of ras proteins in body fluids and tissues
EP0206065A3 (de) * 1985-06-27 1989-04-19 James R. Feramisco Verfahren zum Nachweis von oncogenischen und proto-oncogenischen Proteinen in extrazelligen biologischen Flüssigkeiten
IL79755A0 (en) * 1985-08-21 1986-11-30 Oncogene Science Inc Immunoassay for detection of ras encoded protein
US5262523A (en) * 1987-07-08 1993-11-16 Oncogene Science, Inc. Antibodies reactive with normal and oncogenic forms of the ras p21 protein
ATE258686T1 (de) * 1988-04-22 2004-02-15 Bayer Ag Nachweis, quantifizierung und klassifizierung von ras-proteinen in körperflüssigkeiten und geweben
US6165734A (en) * 1995-12-12 2000-12-26 Applied Spectral Imaging Ltd. In-situ method of analyzing cells
BR9907852A (pt) * 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
WO2001036461A2 (en) * 1999-11-16 2001-05-25 Academisch Ziekenhuis Leiden Compositions and methods for regulating tumor-associated antigen expression
US6489128B1 (en) * 2000-01-24 2002-12-03 Rhode Island Hospital, A Lifespan Partner Methods for detecting cancer of the central nervous system
US20050176002A1 (en) * 2001-10-16 2005-08-11 Mount Sinai Hospital Methods for detecting ovarian cancer
ATE441107T1 (de) * 2002-03-01 2009-09-15 Siemens Healthcare Diagnostics Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von kírperflüssigkeiten
JP2007506068A (ja) * 2003-08-05 2007-03-15 ユーロ−セルティーク エス．エイ． 化学療法耐性モニタリングのためのＥｒｂＢ受容体方法及びキット
US7423150B2 (en) * 2003-10-16 2008-09-09 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of Raf kinase

Also Published As

Publication number Publication date
JP2008547027A (ja) 2008-12-25
ES2349660T3 (es) 2011-01-10
EP1893997A1 (de) 2008-03-05
EP1893997A4 (de) 2009-02-18
CA2612693C (en) 2012-05-08
CA2612693A1 (en) 2007-01-04
DE602006015957D1 (de) 2010-09-16
US20100167324A1 (en) 2010-07-01
WO2007002505A1 (en) 2007-01-04
JP4693902B2 (ja) 2011-06-01
EP1893997B1 (de) 2010-08-04
US20140093890A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
ATE493652T1 (de) Quantitative assays für pdgfr-beta- in körperflüssigkeiten
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
ATE554386T1 (de) Verbesserte immunoassayverfahren
ATE456055T1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
HK1183707A1 (en) Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease (pct)
RU2017126701A (ru) Способ детекции нуклеосом, содержащих нуклеотиды
EA201390150A1 (ru) Способы выявления сигнатур заболевания или патологических состояний в текучих средах организма
BR112015011359A8 (pt) método para indicar uma presença ou não presença de câncer de próstata agressivo, dispositivo de ensaio, kit de teste, produto de programa de computador, e aparelho
ATE312349T1 (de) Differentielle diagnose von neurodegeneration
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
DK1421215T3 (da) Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
ATE445160T1 (de) Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
EP3293522A3 (de) Lipidomik-biomarker zur identifizierung von patienten mit hohem risiko einer koronararterienerkrankung
CY1113403T1 (el) Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων
ATE542139T1 (de) Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
WO2010084327A3 (en) Methods
DE602007007958D1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
ATE476652T1 (de) Quantitative assays für ras p21 in körperflüssigkeiten
ATE412182T1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
CY1113290T1 (el) Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3
CY1117148T1 (el) Βελτιωμενες μεθοδοι ανοσοπροσδιορισμου

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties